摘要
目的:观察前痛定方对Ⅲb型前列腺炎(CP)患者血浆中单胺类神经递质水平的影响。方法:120例Ⅲb型CP患者采用区组随机化方法分配到G1组、G2组和G3组。G1组口服前痛定方;G2组口服可多华片;G3组口服前痛定方及可多华片,疗程均为30 d。治疗前后对所有患者进行前列腺症状评分(NIH-CPSI)、ELISA法检测血浆中单胺类神经递质肾上腺素(NE)、5-羟色胺(5-HT)、多巴胺(DA)水平。结果:治疗前三组间基线特征均衡性良好(P>0.05);治疗后三组NIH-CPSI评分、血浆NE、DA水平降低、血浆5-HT水平升高,但G3组较G1、G2组为佳(P<0.05)。结论:前痛定方能够明显地降低Ⅲb型CP患者NIH-CPSI评分,恢复Ⅲb型CP患者异常的血浆单胺类神经递质水平,显著地改善Ⅲb型CP患者的临床症状。
Objective： To observe the impacts of Qiantongding Prescription on the monoamine neurotransmitters in the blood plasma of Type III chronic prostatitis （ CP ） patients. Methods ： 120 cases of Type ]II CP patients were randomized into three groups.Among them, those in the Group 1 were orally treated with Qiantongding Prescription, those in the Group 2 were orally treated with Cardura tablets, and those in the Group 3 were orally treated with Qiantongding Prescription plus Cardura tablets, with thirty days as the therapeutic session.Before and after treatments, all the patients were assessed with the NIH-CPSI score, and the contents of the monoamine neurotransmitters such as NE, 5-HT and DA in the blood plasma were detected with ELISA methods. Results ： Before treatments, the characteristic of baseline among the three groups was good （ P〉0.05 ） .After the treatments, the NIH-CPSI score and the contents of NE and DA in the blood plasma were increased, and those in the Group 3 were better than those in the other two groups （ P〈0.05 ） .Conclusion ： Qiantongding Prescription could obviously reduce the NIH-CPSI scores of the Type III CP patients, regulate the abnormal contents of monoamine neurotransmitters in the blood plasma and remarkably improve the clinical symptoms.
出处
《辽宁中医药大学学报》
CAS
2013年第10期89-91,共3页
Journal of Liaoning University of Traditional Chinese Medicine
基金
深圳市科技计划项目(201003191)
